Introduction
============

The treatment of unresectable head and neck cancer (HNC) has improved with the use of modern chemotherapy and radiotherapy ([@b1-mco-0-0-1339],[@b2-mco-0-0-1339]). However, locoregional failure remains a major concern, preventing complete cure. Although salvage surgery has the highest disease-eradicating potential, only one-third of patients are eligible ([@b3-mco-0-0-1339]). After surgery, chemotherapy is a frequently preferred option; however, the resulting median survival time is \<9 months ([@b4-mco-0-0-1339]). With the advancement of modern radiation techniques, re-irradiation using advanced technologies, including intensity-modulated radiation therapy and/or stereotactic radiotherapy, has become a promising therapeutic option. The image-guided stereotactic radiotherapy system CyberKnife® enables precise dose delivery over short treatment periods ([@b5-mco-0-0-1339]--[@b9-mco-0-0-1339]). Several institutions, including ours, have reported on the outcome and toxicity of re-irradiation using CyberKnife® hypofractionated stereotactic body radiation therapy (SBRT) ([@b5-mco-0-0-1339]--[@b10-mco-0-0-1339]).

Lethal carotid blowout syndrome (CBOS) was previously investigated in patients with HNC ([@b7-mco-0-0-1339],[@b9-mco-0-0-1339]), and the findings prompted the subsequent investigation of predisposing factors for CBOS ([@b10-mco-0-0-1339]). The presence of ulceration and lymph node irradiation were found to be risk factors for CBOS, and the CBOS index, including carotid invasion of \>180°, was found to be useful for risk factor classification and determination of indications for re-irradiation ([@b10-mco-0-0-1339]). As an increased frequency of AN was observed among CBOS cases in an initial single-institution study by our group ([@b7-mco-0-0-1339]), an assessment of multi-institutional records of patients with HNC was conducted, focusing on AN. The aim of the present study was to investigate the role of AN in tumor control and toxicity following re-irradiation using CyberKnife® SBRT in HNC patients.

Patients and methods
====================

### Patients

The medical records of patients who underwent CyberKnife® SBRT (Accuray; Sunnyvale, CA, USA) in four hospitals \[Soseikai General Hospital (Kyoto, Japan), Osaka University Hospital (Osaka, Japan), Fujimoto Hayasuzu Hospital (Miyakonojo, Japan) and Okayama Kyokuto Hospital (Okayama, Japan)\] between August 2000 and July 2010 were reviewed for inclusion in the present study. Among the patients with HNC who received re-irradiation up to the prescribed dose for residual or recurrent tumors within the irradiated area, only those who satisfied the following criteria were included: Patients who had undergone imaging analysis prior to SBRT to confirm the presence or absence of AN and had completed a course of radical treatment, including previous radiotherapy at ≥40 Gy \[biological equivalent 2-Gy fractions (EQD2) described in detail below\], with or without chemotherapy and surgery. Previous radiotherapy consisted of 40--74.8 Gy/20--62 fractions (1.2--2 Gy fractionation), with estimated EQD2 of 40--75.1 Gy (α/β=10).

A total of 67 patients were considered eligible for assessment. The patient characteristics are listed in [Table I](#tI-mco-0-0-1339){ref-type="table"} nd a representative case of a patient with intratumoral AN is presented in [Fig. 1](#f1-mco-0-0-1339){ref-type="fig"}. The conventional technique using a linear accelerator was used during the first course of radiotherapy. SBRT re-irradiation was performed using the CyberKnife® system. The patients received a median dose of 30 Gy (range, 15--39 Gy) over a median of five daily fractions (range, 1--8 fractions) that were prescribed at D90, D95, or a marginal dose. D90 (D95) was defined as a minimum dose covering 90% (95%) of the planning target volume (PTV). The marginal dose prescription was defined as the percentage (maximum dose, 100%) of the isodose curve covering the PTV. None of the patients received chemotherapy. All irradiated lesions were located inside areas previously subjected to high-dose irradiation. Prior to SBRT, the presence of AN was confirmed by imaging analysis, such as computed tomography (CT) and/or magnetic resonance imaging (MRI), contrast-enhanced if required. AN was identified as a focal area of low density with a surrounding rim of high density and/or enhancement on CT, or a focal area of high signal intensity on T2-weighted images, or a focal area of low signal intensity on T1-weighted images with a surrounding rim of enhancement on MRI ([@b11-mco-0-0-1339]). These interpretations were made by at least one diagnostic radiologist and one radiation oncologist. The presence of mucosal ulceration of the upper aerodigestive tract was determined by visual inspection (fibroscopy if required) and/or imaging analysis (CT and/or MRI). EQD2 was calculated using the linear quadratic model as follows: EQD2=prescription dose × (α/β+dose per fraction)/(α/β+2), where α/β = 10 for tumors and 3 for organs at risk. In principle, follow-up by physical examination was performed at intervals of at least 1 month for the first year and at intervals of 3--6 months thereafter. Examination with imaging methods, such as CT and/or MRI and/or ultrasonography, was performed after 3 and 6 months, 1, 1.5 and 2 years, and at 1-year intervals thereafter, or when local or lymph node recurrence was suspected. Initial response was assessed using the Response Evaluation Criteria in Solid Tumors version 4.0 (<http://www.jcog.jp/doctor/tool/ctcaev4.html>). Written informed consent was obtained from the patients for the publication of their data and accompanying images.

### Statistical analysis

All statistical analyses were performed using Statview 5.0 statistical software (SAS Institute, Inc., Cary, NC, USA). The percentage values were analyzed using the χ^2^ test, and values were compared using Mann-Whitney U test. Cumulative incidences were estimated by the Kaplan-Meier method. The durations were calculated from the first day of CyberKnife® SBRT. Variables that had P-values \<0.05 were further tested by multivariate analysis using a Cox proportional hazards model. The cut-off value was set at the average or median value of each variable if not otherwise stated. All analyses used a significance level of P\<0.05.

Results
=======

### AN is associated with poor prognosis of patients with recurrent HNC following SBRT

The median follow-up time for the surviving patients after SBRT was 17 months (range, 1--122 months). As shown in [Table I](#tI-mco-0-0-1339){ref-type="table"}, the frequency of AN was significantly increased in patients who received surgery, and those who had large, ulcerative tumors; furthermore, the median age in the AN^+^ group was significantly lower compared with that in the AN^−^ group. Thus, younger, postoperative patients with large ulcerative tumors tended to exhibit AN. In particular, AN exhibited a strong correlation with ulceration (P=0.001; [Table I](#tI-mco-0-0-1339){ref-type="table"}). The AN^−^ group exhibited a better initial response rate (15 complete responses + 16 partial responses = 64%) compared with the AN^+^ group (3 complete responses + 3 partial responses = 33%) (P=0.04). The local control (LC) rate in the AN^+^ group was 51%, which was significantly lower compared with that in the AN^−^ group (75%; P=0.01). The median survival time and 1-year survival rates for the AN^+^ and AN^−^ groups were 13.6 vs. 28.2 months (P\<0.001) and 53 vs. 71% (P=0.0004), respectively ([Table II](#tII-mco-0-0-1339){ref-type="table"} and [Fig. 2](#f2-mco-0-0-1339){ref-type="fig"}). PTV, ulceration, primary site (nasopharynx or other) and prescribed dose were statistically significant predisposing factors for reduced overall survival (OS) according to the univariate analysis ([Table II](#tII-mco-0-0-1339){ref-type="table"}). There were statistically significant differences in LC and OS rates between the AN^+^ and AN^−^ groups ([Table II](#tII-mco-0-0-1339){ref-type="table"}, [Fig. 2](#f2-mco-0-0-1339){ref-type="fig"}), indicating poor prognosis for patients with AN.

### Toxicity

A total of 21 patients (31%) experienced grade ≥3 adverse effects. Among them, CBOS was found in 11 patients and resulted in 8 deaths, whereas the 3 remaining patients recovered following intervention. All fatal adverse effects were due to CBOS. A total of 44% (8/18) of patients in the AN^+^ group and 6% (3/49) of patients in the AN^−^ group developed CBOS (P=0.001). The AN^+^ group exhibited a lower CBOS-free survival ratio (65% at 1 year) compared with the AN^−^ group (98% at 1 year; P\<0.0001; [Fig. 2C](#f2-mco-0-0-1339){ref-type="fig"}). In addition, among patients with carotid invasion at ≤180°, only AN^+^ recurrent oral cancer patients exhibited CBOS, whereas among patients with carotid invasion at \>180°, 44% of AN^+^ and 10% of AN^−^ patients developed CBOS (P\<0.01; [Table III](#tIII-mco-0-0-1339){ref-type="table"}). Other grade ≥3 radiation-induced adverse effects included 2 cases of mucositis requiring percutaneous endoscopic gastrostomy, 2 cases of lateral lobe necrosis (grade 4 in 1 case), 5 cases of fistulas and 1 case each of bone necrosis, soft tissue necrosis, visual disturbance and ulceration.

Discussion
==========

To the best of our knowledge, the present study was the first to investigate AN as a prognostic factor in patients with recurrent HNC following re-irradiation using SBRT. Low-density areas on CT and/or water intensity areas on MRI, which may indicate central necrosis in the lymph node and/or ring enhancement in contrast-enhanced images ([@b10-mco-0-0-1339],[@b11-mco-0-0-1339]), are occasionally encountered in a routine clinical examination. However, it remains elusive whether these findings affect the outcome and/or adverse effects of SBRT in patients with recurrent HNC. The presence of AN has been identified as a factor associated with the inflammatory and/or infection process, which weakens the arterial walls and may result in CBOS. In addition, a hypoxic tumor environment indicates a radioresistant and infiltrative nature, which may be associated with worse prognosis. Certain studies have indicated that central necrosis in lymph nodes is indicative of malignancy and poor prognosis with extracapsular extension ([@b12-mco-0-0-1339],[@b13-mco-0-0-1339]). However, patients with human papilloma virus infection have been found to have a better prognosis compared with patients without this infection, and their lymph node metastases frequently display cystic changes ([@b14-mco-0-0-1339]). In the present study, the detailed morphology of AN, such as wall thickness and smoothness, could not be assessed due to the heterogeneous methods of image collection (CT and MRI, with or without contrast enhancement, with the use of different image acquisition techniques and conditions); however, image interpretation for diagnostic purposes should be performed in future studies and the results of the present study should be interpretated with caution.

Patients with fatal CBOS who exhibited AN were encountered in our previous study ([@b7-mco-0-0-1339]). CBOS is one of the most devastating complications of HNC and mainly occurs fas a postoperative complication, particularly in patients with a history of radiotherapy and/or when the tumor compromises the vascular axis ([@b7-mco-0-0-1339]--[@b10-mco-0-0-1339],[@b15-mco-0-0-1339]--[@b17-mco-0-0-1339]). McDonald *et al* ([@b16-mco-0-0-1339]) have reported that CBOS following re-irradiation is a rare \[41/1,554 (2.6%)\] and often fatal (75%) event. Zoumalan *et al* ([@b12-mco-0-0-1339]) reported that 15 of 33 treatment-related deaths (40%) were associated with CBOS in a cohort of 166 patients (overall mortality rate, 9%). Similarly, we also previously reported that CBOS occurred in 8.4% of cases among 381 HNC patients treated with 484 re-irradiation sessions at seven Japanese CyberKnife® institutions, and 69% of the cases were fatal ([@b10-mco-0-0-1339]). In addition, the presence of ulceration in association with carotid invasion at \>180° was an important risk factor for CBOS ([@b11-mco-0-0-1339]). The present study identified AN as an additional risk factor for CBOS in patients with recurrent HNC after SBRT.

The present study had several limitations. Due to the retrospective nature of the study and inclusion of only a small number of patients with a short follow-up period, selection- and physician-based biases may exist. Therefore, the results of the present study should be confirmed in a prospective trial with a larger number of patients with longer follow-up periods. In addition, there were several confounding factors exhibiting a correlation with AN, such as age, postoperative status, tumor volume and ulceration. Therefore, although AN was not found to be an independent risk factor, it should be taken into consideration when determining a patient\'s eligibility for re-irradiation using SBRT.

In conclusion, younger postoperative patients with large and ulcerative tumors tended to exhibit AN. Thus, AN is an important prognostic factor for HNC patients following reirradiation using CyberKnife®, as well as a predictor of fatal CBOS.

![Presentation of a case with intratumoral abscess/necrosis. A 61-year-old man with oropharyngeal cancer (right lateral wall) underwent preoperative radiotherapy at 40 Gy in 20 fractions with intra-arterial chemotherapy (cisplatin) followed by surgery (primary cancer and right neck dissection) and was pathologically classified as T3N0. A recurrent tumor was detected at the primary site with subsequent extension to the Rouvière node 4 months later. The patient then received CyberKnife® hypofractionated stereotactic radiation therapy with 37 Gy administered in 10 fractions. The patient exhibited an intratumoral abscess/necrosis (arrow) with ulceration with a planning target volume of 132 cm^3^. One month after treatment, the patient developed carotid blowout syndrome and succumbed within 1 day.](mco-07-03-0336-g00){#f1-mco-0-0-1339}

![Effect of intratumoral AN on the outcome for patients with head and neck cancer. Solid line, AN^−^ cases; broken line, AN^+^ cases. (A) Local control rate, (B) overall survival rate and (C) CBOS-free survival rate depending on the presence of AN. AN, abscess/necrosis; CBOS, carotid blowout syndrome.](mco-07-03-0336-g01){#f2-mco-0-0-1339}

###### 

Characteristics and treatment factors of patients.

                                                           Abscess/necrosis (−) (n=49)   Abscess/necrosis (+) (n=18)                             
  -------------------------------------------------------- ----------------------------- ----------------------------- ---------------- -------- -----------
  Age (years)                                              63 (45--83)                                                 60 (44--66)               **0.008**
  Gender                                                                                                                                         
    Female                                                 11                            \(22\)                        4                \(22\)   0.690
    Male                                                   38                            \(78\)                        14               \(78\)   
  Disease                                                                                                                                        
    Nasopharyngeal cancer                                  32                            \(65\)                        7                \(39\)   0.070
    Oropharyngeal cancer                                   9                             \(18\)                        8                \(44\)   
    Hypopharyngeal cancer                                  8                             \(16\)                        2                \(11\)   
    Oral cancer                                            0                             \(0\)                         1                \(6\)    
  Irradiated area                                                                                                                                
    Primary site                                           39                            \(80\)                        11               \(61\)   0.110
    Lymph node                                             10                            \(20\)                        7                \(39\)   
    Lymph node alone                                       4                             \(40\)                        2                \(29\)   
    Primary and lymph node                                 6                             \(60\)                        5                \(71\)   
  Ulceration                                                                                                                                     
    No                                                     41                            \(84\)                        9                \(50\)   **0.006**
    Yes                                                    8                             \(16\)                        9                \(50\)   
  Surgical history                                                                                                                               
    No                                                     36                            \(73\)                        8                \(44\)   **0.02**
    Yes                                                    13                            \(27\)                        10               \(56\)   
  Planning target volume (cm^3^)                           13.5 (1--339)                                               53 (5.2--241)             **0.003**
  Treatment interval (months)                              17.6 (3.1--122)                                             24 (8.3--86.2)            0.770
  Response^[a](#tfn1-mco-0-0-1339){ref-type="table-fn"}^   15/16                         \(64\)                        3/3              \(33\)   **0.040**

Complete/partial response. Bold print indicates statistical significance.

###### 

Analysis of prognostic factors.

  Variables                                                                   No. of patients   1-y LC (%)   P-value    MST (months)   1-y OS (%)   P-value
  --------------------------------------------------------------------------- ----------------- ------------ ---------- -------------- ------------ -------------
  Age (years)                                                                                                                                       
    \<70                                                                      53                67           0.46       19.4           69           0.670
    ≥70                                                                       14                73                      20.8           53           
  Sex                                                                                                                                               
    Male                                                                      52                70           0.89       17.8           67           0.280
    Female                                                                    15                64                      48             62           
  PTV (cm^3^)                                                                                                                                       
    ≤40                                                                       44                70           0.54       24.9           76           **0.020**
    \>40                                                                      23                66                      10.3           47           
  Abscess/necrosis (AN)                                                                                                                             
    Yes                                                                       18                51           **0.01**   13.9           53           **\<0.001**
    No                                                                        49                75                      28.2           71           
  Ulceration                                                                                                                                        
    Yes                                                                       17                55           0.05       6.6            38           **\<0.001**
    No                                                                        50                74                      27.5           76           
  Primary cancer type                                                                                                                               
    NPC                                                                       39                77           0.06       42.3           75           **\<0.001**
    Others                                                                    28                54                      13.9           53           
  Treatment interval^[a](#tfn2-mco-0-0-1339){ref-type="table-fn"}^ (months)                                                                         
    ≤30                                                                       38                56           0.05       17.7           61           0.150
    \>30                                                                      29                82                      39.9           72           
  Prescribed dose (EQD2), Gy                                                                                                                        
    ≤40                                                                       34                60           0.14       14.8           60           **0.010**
    \>40                                                                      33                76                      42.3           72           
  Surgical history                                                                                                                                  
    Yes                                                                       23                67           0.59       14.4           65           0.500
    No                                                                        44                69                      24.8           66           

Interval between CyberKnife® stereotactic body radiation therapy and prior radiation therapy. Bold print indicates statistical significance. 1-y LC, one-year local control; MST, median survival time; OS, overall survival; NPC, nasopharygeal cancer; EQD2, biologically effective dose in 2-Gy fractions; PTV, planning target volume.

###### 

Risk factors for CBOS.

  Factors                   No CBOS   CBOS   \%^[a](#tfn3-mco-0-0-1339){ref-type="table-fn"}^
  ------------------------- --------- ------ --------------------------------------------------
  Carotid invasion ≤180°                     
    AN^−^                     20      --     \(0\)
    AN^+^                     1       1      \(50\)
  Carotid invasion \>180°                    
    AN^−^                     26      3      \(10\)
    AN^+^                     9       7      \(44\)

Percentage represents CBOS/(no. CBOS+CBOS). AN, abscess/necrosis; CBOS, carotid blowout syndrome.
